Qatar Investment Authority Backs $132M Funding for Cancer Biotech Firm Artbio
by The Qatar Investment Authority (QIA) has made its first investment in Artbio, a US-headquartered, clinical-stage radiopharmaceutical biotech company pioneering alpha radioligand therapies (ARTs) — an innovative approach to treating various forms of cancer.
QIA participated as a key investor in Artbio’s $132 million Series B funding round, which was co-led by Sofinnova Investments and B Capital. A returning life sciences investment fund also joined the round, alongside existing investors F-Prime, Omega Funds, and Third Rock Ventures, with Alexandria Venture Investments coming on board as a new investor.
The funds will be used to advance the development of ARTs, a next-generation cancer therapy designed to precisely target and destroy cancer cells while minimizing damage to healthy tissue.
This investment continues QIA’s growing interest in the biotech sector. With $524 billion in assets under management, the sovereign wealth fund has been increasing its presence in the US biotech market. In 2023, QIA led a $250 million funding round for Nasdaq-listed BridgeBio Pharma, a company specializing in genetic diseases and cancer therapies.
Through strategic investments like these, QIA is positioning itself at the forefront of medical innovation, supporting companies working on breakthrough treatments with the potential to transform patient care.
